New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2013
16:38 EDTINTC, GOOG, FRX, VMW, GILD, EMCTech, drug companies' stocks could jump with higher R&D spending, Barron's says
Forest Laboratories (FRX), Google (GOOG), EMC (EMC), VMware (VMW), Gilead Sciences (GILD), and Intel (INTC) have increased their Research and Development spending by at least 15%, look reasonably priced, and could continue to rise, Barron's contends. Reference Link
News For GOOG;EMC;VMW;INTC;GILD;FRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 >>
November 18, 2015
13:44 EDTINTCBefore the Move: Watch Intel into tomorrow's analyst day
Chipmaker Intel's (INTC) analyst day tomorrow could yield information on numerous company operations, but Jefferies analyst Mark Lipacis cautions investors that the probability for positive surprises appears low given recent spending outlays. BACKGROUND: Intel, one of the largest semiconductor makers in the world, is scheduled to hold an analyst day on Thursday, November 19. Beyond providing forecasts for its various business segments and remarks on the larger computer market, Intel is expected to provide further clarity on several recent stories, including its memory joint venture with Micron (MU), plans to invest heavily in a Chinese production facility and progression towards chips on the 10 nanometer scale. STRONG OUTLOOK, MILD MEETING: Intel's pending acquisition of Altera (ALTR) and its plans to invest as much as $5.5B in a computer memory facility in Dalian, China leave little room for positive surprises at tomorrow's event in regards to 2016 margins, capital expenditures, or shareholder returns, Jefferies analyst Mark Lipacis said in a recent research note. That said, the analyst views Intel's Chinese facility expansion as part of a "brilliant investment strategy that positions Intel as a partner to China" and "keeps the market open" to its microprocessors, perhaps Intel's more famed business segment. Though the two initiatives are certain to push up near-term debt load, Lipacis takes the longer-term view, reminding investors that Intel has shown consistently strong free cash flow over the past decade, leading him to forecast another $13B in 2016. The year may also bring "a number" of other positives for the company, including more data center wins after the Altera tie-up, potentially renewed sales on a cyclical uptick in PC gaming, and even the possibility of an iPhone chip contract, though Lipacis said none of those points look set to be discussed tomorrow. The analyst kept a Buy rating and $38 price target on the shares while reiterating that Thursday's Intel event may have little in store for those expecting eye-grabbing surprises. PRICE ACTION: Shares of Intel have advanced roughly 0.9% to $32.92 Wednesday afternoon. "Before the Move" is The Fly's recurring series of exclusive stories that identify potentially market moving events, along with analyst predictions, ahead of the news.
11:24 EDTGOOGGoogle eyes YouTube enhancement with VR experiences, DigiTimes says
Subscribe for More Information
09:34 EDTGILDActive equity options trading on open
Subscribe for More Information
November 17, 2015
19:11 EDTGOOGGoogle launches redesigned Google+
Subscribe for More Information
15:40 EDTINTCIntel to host investor meeting
Subscribe for More Information
11:25 EDTGOOGGoogle to fight Russia's antitrust ruling on Android platform, Reuters reports
Subscribe for More Information
11:03 EDTINTCTsinghua Chairman says in talks with U.S.-based chipmaker, Reuters reports
Subscribe for More Information
10:47 EDTGILDBristol-Myers strength attributed to sale chatter
The move higher in shares of Bristol-Myers (BMY) is being attributed by traders to chatter of a sale. The stock is up 2%, or $1.06, to $66.08 in morning trading. The unconfirmed talk has the company possibly approaching Gilead (GILD) about buyout interest. Bristol's market capitalization is just above $110B while Gilead's is just above $150B. Shares of Gilead are up 74c to $104.55.
07:48 EDTINTCHP Enterprise announces alliance with Intel
Subscribe for More Information
06:35 EDTGOOGGoogle's Project Aura working on three new wearables, the Information says
Google's revamped Google Glass project, known as Project Aura, is developing a wearable with a screen and at least one without, the Information reports. Three versions of the head-mounted device are currently in development, though three may be consolidated into two, the report says. The two without a screen rely on bone conduction, much like the original Google Glass, the report says. Reference Link
06:27 EDTINTCIntel November volatility elevated into investor meeting
Subscribe for More Information
November 16, 2015
09:37 EDTINTCActive equity options trading on open
Active equity options trading on open: AAPL FB ORCL BAC SUNE FDX FCX EXPE NFLX MU AMZN INTC TSLA
09:33 EDTGOOGeBay second week of November SSS up 0.4%, ChannelAdvisor says
Subscribe for More Information
09:04 EDTGILDGilead says Phase 3 Zydelig study shows 'clinical benefit'
Gilead announced that its Phase 3 Study 115 evaluating Zydelig added to standard therapy in previously-treated chronic lymphocytic leukemia patients will be unblinded early. The DMC recommendation is based upon a predefined interim analysis indicating a statistically significant benefit in efficacy for progression-free survival and overall survival in patients receiving Zydelig plus bendamustine and rituximab, compared to those receiving only bendamustine and rituximab. The safety profile of Zydelig was consistent with prior studies. Detailed results from this study will be presented during a late-breaking abstracts session at the Annual Meeting of the American Society of Hematology in Orlando, Florida taking place December 5-8. "The clinical benefit observed in this Phase 3 study adds to the body of evidence demonstrating the potential of Zydelig-containing treatment regimens for patients with previously treated CLL," said Norbert W. Bischofberger, PhD, Gilead's Executive Vice President, Research and Development and Chief Scientific Officer. "We look forward to sharing the detailed scientific data with the hematology community at the upcoming ASH meeting."
06:27 EDTGOOGYandex extends Google antitrust battle to EU, Bloomberg reports
Subscribe for More Information
November 15, 2015
20:17 EDTGILDGilead presents results from four Phase 3 studies of sofosbuvir/velpatasvir
Subscribe for More Information
15:47 EDTGILDGilead reports data from multiple studies of Viread, TAF, others
Subscribe for More Information
November 13, 2015
11:57 EDTGOOGGoogle rolls out Chrome beta for iOS, 9to5Mac reports
Subscribe for More Information
09:35 EDTINTCActive equity options trading on open
Active equity options trading on open: AAPL CSCO FB BAC BABA MSFT NFLX INTC JCP AMZN C
09:20 EDTEMCCisco CEO says 'certainly have ability to acquire'
Subscribe for More Information
1 | 2 | 3 | 4 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use